Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Polatuzumab Vedotin→

Polatuzumab Vedotin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1313206-42-6
Molecular formula
C6670H10317N1745O2087S40
Molecular weight
149625.39 g/mol
Drug class
CD79b-directed antibody-drug conjugate (ADC)microtubule-disrupting antineoplastic
Mechanism of action
The antibody component binds CD79b on B cells and is internalised. Intracellular linker cleavage releases monomethyl auristatin E (MMAE), which binds microtubules, inhibits cell division and induces apoptosis.
Indications / reported uses
  • In combination regimens for adults with previously untreated diffuse large B-cell lymphoma or relapsed/refractory diffuse large B-cell lymphoma, according to the applicable product label and treatment setting.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20a16ab2-f338-4abb-9dcd-254bd949a2bc · https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=20a16ab2-f338-4abb-9dcd-254bd949a2bc&version=14

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Polatuzumab Vedotin Environmental Risk Assessment (ERA) (the Polatuzumab Vedotin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.